Your session is about to expire
← Back to Search
Other
Allergen Inhalation Challenge for Asthma (MATT Trial)
N/A
Waitlist Available
Led By Gail Gauvreau, PhD
Research Sponsored by McMaster University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Men or women aged 18 to 75 years inclusive at the first screening visit with mild atopic asthma
Agree to withhold use of inhaled short-acting β2-agonist for 8 hours before all study visits where spirometry is performed
Must not have
Current or history of lung disease other than mild stable allergic asthma
Upper or lower respiratory infection or asthma exacerbation within 4 weeks of first study visit
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 hours post-allergen challenge
Summary
This trial will test how well the lungs work and analyze samples taken before and after participants with mild allergic asthma are exposed to allergens and control substances through inhalation.
Who is the study for?
This trial is for adults aged 18-75 with mild atopic asthma, who can perform required procedures and likely to follow the study plan. They must have a positive skin test for allergens, not exercise before visits, avoid certain asthma medications, and be non-smokers or long-term ex-smokers without significant past smoking history.
What is being tested?
The study tests lung function after inhaling either an allergen or saline (a control substance). It involves measuring changes in breathing and analyzing biological samples to understand inflammation caused by allergens in people with mild allergic asthma.
What are the potential side effects?
While specific side effects are not listed, inhalation challenges may cause temporary respiratory discomfort or exacerbate asthma symptoms such as wheezing or shortness of breath due to induced inflammation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 75 years old with mild atopic asthma.
Select...
I agree not to use my short-acting inhaler for 8 hours before study visits with lung function tests.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have no lung conditions except for mild, stable allergic asthma.
Select...
I haven't had a respiratory infection or severe asthma in the last 4 weeks.
Select...
I only use quick-relief asthma inhalers occasionally, not regularly.
Select...
I have smoked in the last year or have a history of heavy smoking.
Select...
I am not pregnant, breastfeeding, nor planning to become pregnant during the study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 7 hours post-allergen challenge
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 hours post-allergen challenge
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in FEV1
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Allergen ChallengeExperimental Treatment1 Intervention
Inhaled allergen
Group II: Diluent ChallengePlacebo Group1 Intervention
Inhaled saline
Find a Location
Who is running the clinical trial?
McMaster UniversityLead Sponsor
917 Previous Clinical Trials
2,616,339 Total Patients Enrolled
20 Trials studying Asthma
919 Patients Enrolled for Asthma
Gail Gauvreau, PhDPrincipal InvestigatorMcMaster University
15 Previous Clinical Trials
570 Total Patients Enrolled
9 Trials studying Asthma
472 Patients Enrolled for Asthma